Daniel Joseph OConnell - Jan 17, 2023 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role
President and CEO, Director
Signature
/s/ Katherine Denby, Attorney-in-Fact
Stock symbol
ABOS
Transactions as of
Jan 17, 2023
Transactions value $
$0
Form type
4
Date filed
1/18/2023, 03:22 PM
Previous filing
Jan 21, 2022
Next filing
Jan 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABOS Common Stock Award $0 +114K +4245.81% $0.00 117K Jan 17, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABOS Employee Stock Option (right to buy) Award $0 +473K $0.00 473K Jan 17, 2023 Common Stock 473K $6.11 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date.
F2 The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.